Technical Analysis for CALT - Calliditas Therapeutics AB

Grade Last Price % Change Price Change
D 21.01 -2.22% -0.48
CALT closed down 2.22 percent on Thursday, March 28, 2024, on 14 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Fell Below 20 DMA Bearish -2.22%
Fell Below 50 DMA Bearish -2.22%
MACD Bearish Centerline Cross Bearish -2.22%
Inside Day Range Contraction -2.22%
Crossed Above 20 DMA Bullish -3.84%
Crossed Above 50 DMA Bullish -3.84%
MACD Bullish Centerline Cross Bullish -3.84%
Gapped Down Weakness -3.84%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 5 hours ago
Fell Below Previous Day's Low about 8 hours ago
Down 2 % about 8 hours ago
Down 1% about 8 hours ago
10 DMA Resistance 1 day ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Calliditas Therapeutics AB Description

Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Health Sciences Pharmacy Medication Pharmaceutical Products Kidney Disease Renal Disease Pharmaceutics

Is CALT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 29.3
52 Week Low 15.25
Average Volume 8,126
200-Day Moving Average 19.26
50-Day Moving Average 21.73
20-Day Moving Average 21.81
10-Day Moving Average 21.59
Average True Range 0.85
RSI (14) 44.75
ADX 11.36
+DI 23.31
-DI 25.34
Chandelier Exit (Long, 3 ATRs) 20.80
Chandelier Exit (Short, 3 ATRs) 22.86
Upper Bollinger Bands 23.17
Lower Bollinger Band 20.45
Percent B (%b) 0.21
BandWidth 12.49
MACD Line -0.08
MACD Signal Line 0.00
MACD Histogram -0.0763
Fundamentals Value
Market Cap 563.82 Million
Num Shares 26.8 Million
EPS -1.60
Price-to-Earnings (P/E) Ratio -13.13
Price-to-Sales 0.48
Price-to-Book 17.01
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.01
Resistance 3 (R3) 21.01 21.01 21.01
Resistance 2 (R2) 21.01 21.01 21.01 21.01
Resistance 1 (R1) 21.01 21.01 21.01 21.01 21.01
Pivot Point 21.01 21.01 21.01 21.01 21.01
Support 1 (S1) 21.01 21.01 21.01 21.01 21.01
Support 2 (S2) 21.01 21.01 21.01 21.01
Support 3 (S3) 21.01 21.01 21.01
Support 4 (S4) 21.01